Zebrafish: Preclinical Screening and Toxicity Assessment

Zebrafish offer a nonclinical model for the high-throughput screening of drug compounds, including toxicity assessment, with resolution at the cellular level in living vertebrate organisms. لعبة بينغو   These small, freshwater, tropical fish share genetic and...

Adverse Preclinical Events – Now What?

Drug development is a complicated, often convoluted process.  The ability to predict drug toxicity in humans from nonclinical data remains a major challenge. قوانين البوكر   Since you can’t “erase” an adverse event, optimization of preclinical dose...

Drug Labels: Toxicity or Information Overload?

Side effect overload on drug labels has less to do with true toxicity and drug safety than with manufacturer liability as many people present addiction to drugs and that’s why professional help for drug addiction is important in society.  Examination of more...

Translational Toxicology: Biomarker Development

Biomarker use in translational medicine is predicated upon preclinical qualification and validation – 2 distinct steps in the biomarker development process. ivermectina tiene penicilina   Prior to issue in 2009 (EMA) and 2010 (FDA, PMDA) of the renal-specific...

Drug Abuse Liability Testing

Any new drug that penetrates the central nervous system must receive some preclinical analysis of abuse liability potential (Draft Guidance).  Usually, it is determined through prior knowledge of chemistry and/or pharmacology of the candidate’s drug class that...

Turbulent Blood Flow may Increase Cardiovascular Risk

By utilizing the basic principles of hemodynamics and hydraulics, research suggests that fluid retention is detrimental for the cardiovascular system because it increases the likelihood of turbulent blood flow, regardless of whether or not blood pressure is raised....